BIOMAT Database Logo BIOMAT Database Logo

Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein. 1994

A A Budayr, and E Zysset, and A Jenzer, and D Thiébaud, and P Ammann, and R Rizzoli, and F Jaquet-Müller, and J P Bonjour, and B Gertz, and P Burckhardt
Department of Veterans Affairs Medical Center, San Francisco, California.

Parathyroid hormone-related protein (PTHrP) is the primary mediator of hypercalcemia in patients with malignancy-associated hypercalcemia. We conducted this study to examine the effects of treatment with a bisphosphonate on serum PTHrP. We analyzed 41 episodes of hypercalcemia occurring in 38 patients: 22 patients received alendronate, and 16 were treated with pamidronate. At baseline, 29 patients had an increased serum PTHrP (group I) and 9 had low or undetectable levels (group II). The two groups did not differ significantly in baseline hypercalcemia (3.26 versus 3.41 mM) or the response of serum calcium to therapy. Serum calcium was normalized in 88% of group I and 70% of group II patients. Lowering of the mean calcium level was not associated with a change in the level of PTHrP in group I patients (40.2 versus 36.7 pgEq/ml) or group II patients. We also analyzed data on serum PTH and 1,25-(OH)2D in 20 of the patients. Serum PTH rose with treatment in group I patients (9.7-40.2 pg/ml, p < 0.05), as did the serum 1,25-(OH)2D (19.1-32.4 pg/ml, p < 0.001). Similarly, treatment of group II patients was associated with an increase in serum PTH (9.8-37.2 pg/ml) and serum 1,25-(OH)2D (22.9-40.2 pg/ml). The individual increases in 1,25-(OH)2D levels associated with therapy could not be predicted from the level of PTHrP or the changes in levels of serum calcium or PTH. Our data show that effective treatment of malignancy-associated hypercalcemia is not associated with a consistent change in serum levels of PTHrP. Therapy is associated with a variable increase in the serum levels of PTH and 1,25-(OH)2D.

UI MeSH Term Description Entries
D008297 Male Males
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D010758 Phosphorus A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions. Black Phosphorus,Phosphorus-31,Red Phosphorus,White Phosphorus,Yellow Phosphorus,Phosphorus 31,Phosphorus, Black,Phosphorus, Red,Phosphorus, White,Phosphorus, Yellow
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004164 Diphosphonates Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents. Bisphosphonate,Bisphosphonates
D005260 Female Females

Related Publications

A A Budayr, and E Zysset, and A Jenzer, and D Thiébaud, and P Ammann, and R Rizzoli, and F Jaquet-Müller, and J P Bonjour, and B Gertz, and P Burckhardt
Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy.
May 1998, Leukemia & lymphoma,
A A Budayr, and E Zysset, and A Jenzer, and D Thiébaud, and P Ammann, and R Rizzoli, and F Jaquet-Müller, and J P Bonjour, and B Gertz, and P Burckhardt
Circulating parathyroid hormone-related protein (109-141) in malignancy-associated hypercalcemia.
February 1996, Japanese journal of clinical oncology,
A A Budayr, and E Zysset, and A Jenzer, and D Thiébaud, and P Ammann, and R Rizzoli, and F Jaquet-Müller, and J P Bonjour, and B Gertz, and P Burckhardt
Parathyroid hormone-related protein of humoral hypercalcemia of malignancy.
January 1990, Advances in clinical chemistry,
A A Budayr, and E Zysset, and A Jenzer, and D Thiébaud, and P Ammann, and R Rizzoli, and F Jaquet-Müller, and J P Bonjour, and B Gertz, and P Burckhardt
Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
October 1999, The Journal of clinical endocrinology and metabolism,
A A Budayr, and E Zysset, and A Jenzer, and D Thiébaud, and P Ammann, and R Rizzoli, and F Jaquet-Müller, and J P Bonjour, and B Gertz, and P Burckhardt
Parathyroid hormone-related protein, parathyroid hormone, and vitamin D in hypercalcemia of malignancy.
January 2000, Clinica chimica acta; international journal of clinical chemistry,
A A Budayr, and E Zysset, and A Jenzer, and D Thiébaud, and P Ammann, and R Rizzoli, and F Jaquet-Müller, and J P Bonjour, and B Gertz, and P Burckhardt
Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody.
October 2003, Seminars in oncology,
A A Budayr, and E Zysset, and A Jenzer, and D Thiébaud, and P Ammann, and R Rizzoli, and F Jaquet-Müller, and J P Bonjour, and B Gertz, and P Burckhardt
Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia.
November 1989, Annals of internal medicine,
A A Budayr, and E Zysset, and A Jenzer, and D Thiébaud, and P Ammann, and R Rizzoli, and F Jaquet-Müller, and J P Bonjour, and B Gertz, and P Burckhardt
Humoral hypercalcemia of malignancy: role of parathyroid hormone-related protein.
January 1994, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
A A Budayr, and E Zysset, and A Jenzer, and D Thiébaud, and P Ammann, and R Rizzoli, and F Jaquet-Müller, and J P Bonjour, and B Gertz, and P Burckhardt
Humoral hypercalcemia of malignancy. The role of parathyroid hormone-related protein.
September 1989, Endocrinology and metabolism clinics of North America,
A A Budayr, and E Zysset, and A Jenzer, and D Thiébaud, and P Ammann, and R Rizzoli, and F Jaquet-Müller, and J P Bonjour, and B Gertz, and P Burckhardt
Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein.
January 1994, Annual review of medicine,
Copied contents to your clipboard!